Assenagon Asset Management S.A. Invests $33,000 in scPharmaceuticals, Inc. (NASDAQ:SCPH)

Assenagon Asset Management S.A. acquired a new position in scPharmaceuticals, Inc. (NASDAQ:SCPH) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 12,430 shares of the company’s stock, valued at approximately $33,000.

Several other institutional investors also recently bought and sold shares of SCPH. King Luther Capital Management Corp boosted its holdings in scPharmaceuticals by 28.4% during the 4th quarter. King Luther Capital Management Corp now owns 2,857,910 shares of the company’s stock valued at $10,117,000 after acquiring an additional 632,120 shares during the period. Nantahala Capital Management LLC increased its holdings in shares of scPharmaceuticals by 33.3% in the 4th quarter. Nantahala Capital Management LLC now owns 1,000,000 shares of the company’s stock worth $3,540,000 after purchasing an additional 250,000 shares in the last quarter. Apis Capital Advisors LLC increased its holdings in shares of scPharmaceuticals by 146.3% in the 4th quarter. Apis Capital Advisors LLC now owns 394,000 shares of the company’s stock worth $1,395,000 after purchasing an additional 234,000 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of scPharmaceuticals by 16.7% in the 4th quarter. Geode Capital Management LLC now owns 750,493 shares of the company’s stock worth $2,657,000 after purchasing an additional 107,151 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of scPharmaceuticals in the 4th quarter worth $318,000. 89.52% of the stock is currently owned by hedge funds and other institutional investors.

scPharmaceuticals Trading Down 2.0%

Shares of NASDAQ SCPH opened at $3.84 on Friday. The business’s 50 day moving average is $3.17 and its two-hundred day moving average is $3.17. The company has a debt-to-equity ratio of 3.86, a current ratio of 5.48 and a quick ratio of 4.61. scPharmaceuticals, Inc. has a 1-year low of $1.94 and a 1-year high of $5.65. The stock has a market capitalization of $202.71 million, a P/E ratio of -2.01 and a beta of 0.36.

scPharmaceuticals (NASDAQ:SCPH) last released its earnings results on Wednesday, May 14th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.06). The business had revenue of $11.75 million for the quarter, compared to the consensus estimate of $11.63 million. scPharmaceuticals had a negative net margin of 216.24% and a negative return on equity of 594.07%. As a group, research analysts expect that scPharmaceuticals, Inc. will post -1.53 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on SCPH shares. Maxim Group dropped their price target on scPharmaceuticals from $20.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, March 20th. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of scPharmaceuticals in a research report on Thursday, March 20th.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.